rs141261442
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 1P and 4B. PP3BS2
The NM_001105206.3(LAMA4):c.4645A>T(p.Asn1549Tyr) variant causes a missense change. The variant allele was found at a frequency of 0.000303 in 1,613,780 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N1549S) has been classified as Likely benign.
Frequency
Consequence
NM_001105206.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LAMA4 | NM_001105206.3 | c.4645A>T | p.Asn1549Tyr | missense_variant | 33/39 | ENST00000230538.12 | NP_001098676.2 | |
LOC107986633 | XR_001744299.2 | n.439+3876T>A | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LAMA4 | ENST00000230538.12 | c.4645A>T | p.Asn1549Tyr | missense_variant | 33/39 | 1 | NM_001105206.3 | ENSP00000230538 | A1 |
Frequencies
GnomAD3 genomes AF: 0.000204 AC: 31AN: 152216Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000187 AC: 47AN: 250826Hom.: 0 AF XY: 0.000184 AC XY: 25AN XY: 135578
GnomAD4 exome AF: 0.000313 AC: 458AN: 1461564Hom.: 0 Cov.: 31 AF XY: 0.000296 AC XY: 215AN XY: 727072
GnomAD4 genome AF: 0.000204 AC: 31AN: 152216Hom.: 0 Cov.: 33 AF XY: 0.000202 AC XY: 15AN XY: 74362
ClinVar
Submissions by phenotype
Dilated cardiomyopathy 1JJ Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 19, 2023 | This sequence change replaces asparagine, which is neutral and polar, with tyrosine, which is neutral and polar, at codon 1542 of the LAMA4 protein (p.Asn1542Tyr). This variant is present in population databases (rs141261442, gnomAD 0.04%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with LAMA4-related conditions. ClinVar contains an entry for this variant (Variation ID: 178051). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Sep 06, 2021 | - - |
not provided Uncertain:2
Uncertain significance, no assertion criteria provided | provider interpretation | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Jun 12, 2017 | Given that the LAMA4 gene is weakly associated with hypertrophic cardiomyopathy, that one report of this variant did not segregate with disease in a family, and the high prevalence of this variant in the general population, we consider this variant a variant of uncertain significance, likely benign and we do not feel it is suitable for assessing risk in healthy relatives ("predictive genetic testing"). The LAMA4 gene is weakly associated with cardiomyopathy; specifically, it is associated with dilated cardiomyopathy. Missense variation in the LAMA4 gene slightly increases the chance that a carrier will develop cardiomyopathy (Walsh et al 2016). This variant is present in ClinVar, where it is classified by two labs as a variant of uncertain significance. It has been seen at least two patients. Another variant at this codon, p.Asn1542Ser is classified as benign in ClinVar by 4 laboratories. This variant has not been reported in the literature; however, it was presented in a case example of a patient with dilated cardiomyopathy. The p.Asn1542Tyr variant was identified in a patient with dilated cardiomyopathy. However, this patient also had a pathogenic variant identified in MYBPC3. Furthermore, it did not segregate with disease in another family member (case presentation by Amy Sturm, https://ccme.osu.edu/WebCastsFiles/669Familial%20Heart%20Disease%20-%204.pdf) Per the test report, Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0")." The asparagine at codon 1542 is completely conserved across species, as are neighboring amino acids. The variant was reported online in 55 of 138,307 individuals in the Genome Aggregation Consortium Dataset (gnomAD; http://gnomad.broadinstitute.org/), which currently includes variant calls on >140,000 unrelated individuals of African, Asian, European, Ashkenazi, Latino descent. Specifically, the variant was observed in 47 of 63,210 individuals of European descent (MAF=0.04%), 4 of 12,014 individuals of African descent, 2 of 17,187 individuals of Latino descent and 2 of 3,224 individuals of other descent. The phenotype of those individuals is not publicly available. The dataset is comprised of multiple cohorts, some of which were recruited from the general population, others were enriched for common cardiovascular disease. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Sep 30, 2024 | Identified in patients with cardiomyopathy in published literature, including one pediatric patient; several patients harbored additional cardiogenetic variants (PMID: 31568572, 30847666); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as p.(N1549Y); This variant is associated with the following publications: (PMID: 31333075, 30847666, 31568572) - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jul 03, 2013 | The Asn1542Tyr variant in LAMA4 has not been reported in individuals with cardio myopathy, but has been identified in 4/8600 European American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/; dbSNP rs1412 61442). Computational analyses (biochemical amino acid properties, conservation, AlignGVGD, PolyPhen2, and SIFT) do not provide strong support for or against an impact to the protein. Additional information is needed to fully assess the cli nical significance of this variant. - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Jan 07, 2016 | - - |
Primary familial hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | research | Klaassen Lab, Charite University Medicine Berlin | Jul 03, 2019 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 27, 2023 | The p.N1542Y variant (also known as c.4624A>T), located in coding exon 32 of the LAMA4 gene, results from an A to T substitution at nucleotide position 4624. The asparagine at codon 1542 is replaced by tyrosine, an amino acid with dissimilar properties. This variant has been detected in individuals from a cohort with various types of cardiomyopathy; however, details were limited, and each individual also had additional variants in other cardiac-related genes (van Lint FHM et al. Neth Heart J. 2019 Jun;27(6):304-309). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at